What is PrismRA?
If your RA is flaring up and you’re feeling unwell, then your doctor may suggest starting or escalating your dose for a type of medication called TNF inhibitor therapy. This drug class includes Enbrel®, Humira®, Simponi®, Remicade®, Cimzia® and others. With these as well as other drugs available, it can be hard to know which one is best for you or if you should continue your current therapy.
The Prism RA® test is a laboratory test that tells you if TNF inhibitor therapies are less likely to work for you.1 Every person is different and will respond to medications differently. Based on information from the PrismRA test, your provider may find that TNF inhibitor therapy is a solid choice for you or that a different type of medication might give you the best chance of feeling better.
There’s a new way to select medication for rheumatoid arthritis
The PrismRA test should be considered when your doctor is starting or changing your RA medication. Studies show that patients have the best chance for long-term relief when they respond well to their medication. With PrismRA, your provider can make more informed treatment decisions, improving your quality
What is a molecular signature and how can it predict treatment response?
Like fingerprints, molecular signatures are unique. They combine a set of personalized biological features, including RNA and proteins, to determine an individual’s genetic makeup. Molecular signatures can even be used to predict how a person will experience their disease and how they will respond to different targeted therapies, like TNFi therapies. When patients fail to respond to a TNFi therapy, it is likely because his or her RA symptoms are not sufficiently caused by the same protein that TNFi therapies target.